CTCX 0.51 Carmell Therapeutics Corporation
| Range: | 0.29-4.313 | Vol Avg: | 4266493 | Last Div: | 0 | Changes: | 0.06 |
| Beta: | 0.29 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Sep 23 2021 | Empoloyees: | 9 | ||
| CUSIP: | 142922103 | CIK: | 0001842939 | ISIN: | US1429221039 | Country: | US |
| CEO: | Ms. Kendra Bracken-Ferguson | Website: | https://www.carmellrx.com | ||||
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow